Form PTO-1449 18 1

US. Department of Commerce

Atty. Docket No. Serial No. 51400-B/JPW/AJM/MML 09/940,727
Applicant

Donald W. Landry

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date
August 28, 2001

Group

//// 2

11	2	PA	TE	TV	DO	CI	IM	IENTS	
υ.	· O ·	1 /3	1 1		$\mathbf{v}\mathbf{v}$	~~~	<i>)</i>] 7]		

Examiner Initial		Document Number				mber		Date	Name	Class	Subclass	Filing Date if Appropriate	
OM	AA	3	8	8	8	8	6	6	6/10/75	Leute, et al.;	200	292	
14	NB	3	9	1	7	5	8	2	11/4/75	Soffer, et al.;	200	12/	
	A P	3	9	7	5	2	3	7	8/17/76	Rubenstein et al.;		/	
BAI	M	4	0	4	5	4	2	0	8/30/77	Soffer, et al.;	200	1/2	
	W	4	1	9	7	2	3	7	4/8/80	Leute, et al.;	200	1/2 /	
	IF	4	2	0	3	8	0	2	5/20/80	Rubenstein, et al.;	475	188	
	Uf	4	2	3	5	8	6	4	11/25/80	Kaul, et al.;	424	1.	
	AH	4	6	5	9	5	6	7	4/21/87	Tramontano, et al.;	424	85	
CAY	M	4	7	9	2	4	4	6	12/20/88	Kim, et al.;	424	8518	

FOREIGN PATENT DOCUMENTS

	D	oci	ume	ent i	Nu	mb	er	Date	Country	Class	Subclass	Translation		
												Yes	No	
AT	9	3	2-	0	0	7	6-	10/14/93	wo					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Abraham, et al., "N-Modified Analogues of Cocaine: Synthesis and Inhibition of Binding to the Cocaine Receptor," J. Med. Chem., 35: 141-144 (1992);

Ambre, J., et al., "Urinary excretion of ecgonine methyl ester, a major metabolite of cocaine in humans," *J. Anal. Toxicol.*, 8:23-25 (1984);

Ambre, J., "The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data," J. Anal. Toxicol., 9:241-245 (1985);

Basmadjian et al., "Generation of Polyclonal Catalytic Antibodies Against Cocaine Using Transition State Analogs of Cocaine Conjugated to Diphtheria Toxoid," Chem. & Pharm. Bull., Vol. 43, No., 1,1:1902-1911 (1995);

EXAMINER ANALYMAN DATE CONSIDERED 9/17/02

*EXAMINER: mitial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449

Ø.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Serial No. Atty. Docket No. 51400-B/JPW/AJM/MML | 09/940,727

Applicant

Donald W. Landry

Filing Date August 28, 2001 Group

U.S. PATENT DOCUMENTS

Examiner Initial			Do	cum	ent	Nur	nber	•	Date	Name	Class	Subclass	Filing Date if Appropriate
A	Ab	4	9	6	3	3	5	5	10/16/90	Kim, et al.;	42K	85.8	
	AP	5	0	3	0	7	1	7	7/9/91	Tramontano, et al.;	570	387	
	AQ	5	0	7	9	1	5	2	1/7/92	Benkovic, et al.;	475	125	
	AR	5	2	0	2	2	7_	0	4/13/93	Ungemach, et al.;	470	537	
	45	5	4	6	3	0	2	8	10/31/95	Landry, et al.;	530	405	
	AT	5	9	4	8	6	5	8	9/7/99	Landry;	475	188,5	
	AL	5	9	7	7	3	1	4	11/2/99	Landry, et al.;	570	381/	
	A	5	9	9	0	2	8	5	11/23/99	Landry, et al.;	5311	391.1	

FOREIGN PATENT DOCUMENTS

	Document Number							Date	Country		Class	Subclass	Translation		
													Yes	No	
										• "					
1.															

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Chandrakumar, et al., "Phenylphosphonate monoester analogs of cocaine," Bioorg. & Medic. Chem. Let., 3:309-312 (1993);

et al., "Antibody-Catalyzed Degradation of Cocaine, Landry, Science, 259:1899-1901 (1993);

Landry, "Anti-cocaine catalytic antibodies: A Novel Approach to Addiction," Abstracts of Papers Amer. Chem. Soc., 209, No. 1-2,

ANYL 19, Abstract No. XP000992924 (1995);

"Anti-cocaine catalytic antibodies: Landry et al., Approach To The Problem Of Addiction," Journal of Addictive Diseases, Vol. 16, No. 3:1-17 (1997);

al., "2 beta-substituted Analogues of Cocaine. Synthesis and Inhibition of Binding to the Cocaine Receptor." J. Med. Chem. 35:135-140 (1992);

XAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

÷	/	6	7 =	ากซ		aj.									
	(APP	12	, 100		<u>-</u>						heet 3			
Form PT	O-14	49	7/T o 7	m Ki					of Commerce mark Office	Atty. Docket No. Serial No. 51400-B/JPW/AJM/MML 09/940,727					
								OSURE CI		Applicant Donald V	V. Landry				
		((Use	sev	vera	al she	eets	if necessar	ry)	Filing Date August 2		Group /	52		
								U.S. PA	TENT DOCUMENT	rs					
Examiner Initial		D	ocum	ent	Nun	nber		Date	Name	Class	Subclass	Filing Date if Appropriate			
			-		-		+	<u> </u>							
							J	FOREIGN	PATENT DOCUMI	ENTS	•				
		Doc	eum	ent	Nu	mbe	r	Date	Country	Class	Subclass	Tra	nslation		
				_			_					Yes	No		
			┦—	<u> </u>	_		\dashv					 			
			╀	-	-		_						-		
			-	<u> </u>	-	\vdash	\dashv								
			LIF	D I	700	LLL TIM	IFN	TS (Includ	l ling Author, Title, D	ate Pertine	ent Pages Et				
DN	BB	Schi	ılt		Р.	G.,	"	The inte	erplay between talysts," Scie	chemist	ry and b	iology	/ in the		
M	100		non	tar					talytic antibo						
M	BO	Tran	non	ta: ym	no, es,	, e1 ," د	t a	al., "Ar Am. Che	ntibody cataly em. Soc., 110:	sis app 2282-22	roaching 86 (1988)	the a	ctivit		
M		site	e e:	lio	cit	ed	by	mechan	hemical react: istic design o 83:6736-6740	of a syn	thetic an	body tigen	bindin ," <i>Proc</i>		

EXAMINER

DATE CONSIDERED

No.,25, 5881-5890 (1996).

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Yang, et al., "Anti-Cocaine Catalytic Antibodies: A Synthetic Approach To Improved Antibody Diversity," *J. Am. Chem. Soc.*, 118: